Medicenna Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
17
- Stock Symbol
-
MDNA
- Investments
-
1
- Share Price
-
$1.49
- (As of Monday Closing)
Medicenna Therapeutics General Information
Description
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Contact Information
Website
www.medicenna.comCorporate Office
- 2 Bloor Street West
- 7th Floor
- Toronto, Ontario M4W 3E2
- Canada
Corporate Office
- 2 Bloor Street West
- 7th Floor
- Toronto, Ontario M4W 3E2
- Canada
Medicenna Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.49 | $1.53 | $0.15 - $2.19 | $114M | 76.4M | 70.6K | -$0.17 |
Medicenna Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2023 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 |
|---|---|---|---|---|
| EV | 3,205 | 18,668 | 55,108 | 188,116 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (12,415) | (8,276) | (18,025) | (13,271) |
| Net Income | (11,417) | (7,589) | (18,001) | (13,064) |
| Total Assets | 17,540 | 26,945 | 18,788 | 33,472 |
| Total Debt | 0 | 0 | 0 | 27 |
Medicenna Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medicenna Therapeutics Comparisons
Industry
Financing
Details
00000
000000
Medicenna Therapeutics Competitors (54)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Xilio Therapeutics | Formerly VC-backed | Waltham, MA | 00 | 00000 | 000000000 | 00000 |
| OncoResponse | Venture Capital-Backed | Houston, TX | 00 | 00000 | 0000000000 | 00000 |
| Ember Therapeutics | Formerly VC-backed | New York, NY | 00 | 000.00 | 000000000000 | 000.00 |
| Xenetic Bioscience | Corporation | Framingham, MA | 0 | 000.00 | 000000000 | 000.00 |
| BioNTech | Formerly VC-backed | Mainz, Germany | 0000 | 00.000 | 00000000 | 00.000 |
Medicenna Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Medicenna Therapeutics Executive Team (13)
| Name | Title | Board Seat |
|---|---|---|
| Fahar Merchant Ph.D | Chief Executive Officer & Chairman | |
| David Hyman | Chief Financial Officer & Head of Finance | |
| Bradford Brinton | Director, Corporate Development | |
| Rosemina Merchant | Executive | |
| Mann Muhsin MD | Chief Medical Officer |
Medicenna Therapeutics Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Albert Beraldo | Self | Board Member | 000 0000 |
| Fahar Merchant Ph.D | Medicenna Therapeutics | Chief Executive Officer & Chairman | 000 0000 |
| John Geltosky | Self | Board Member | 000 0000 |
| John Sampson | Self | Board Member | 000 0000 |
| Karen Dawes | Self | Board Member | 000 0000 |
Medicenna Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Medicenna Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Medicenna Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| A2 Acquisition | 01-Mar-2017 | 0000000000 | Special Purpose Acquisition Company (SPAC) | 00000 000 |
Medicenna Therapeutics FAQs
-
When was Medicenna Therapeutics founded?
Medicenna Therapeutics was founded in 2011.
-
Who is the founder of Medicenna Therapeutics?
Fahar Merchant Ph.D and Rosemina Merchant are the founders of Medicenna Therapeutics.
-
Who is the CEO of Medicenna Therapeutics?
Fahar Merchant Ph.D is the CEO of Medicenna Therapeutics.
-
Where is Medicenna Therapeutics headquartered?
Medicenna Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Medicenna Therapeutics?
Medicenna Therapeutics has 17 total employees.
-
What industry is Medicenna Therapeutics in?
Medicenna Therapeutics’s primary industry is Biotechnology.
-
Is Medicenna Therapeutics a private or public company?
Medicenna Therapeutics is a Public company.
-
What is Medicenna Therapeutics’s stock symbol?
The ticker symbol for Medicenna Therapeutics is MDNA.
-
What is the current stock price of Medicenna Therapeutics?
As of 16-Sep-2024 the stock price of Medicenna Therapeutics is $1.49.
-
What is the current market cap of Medicenna Therapeutics?
The current market capitalization of Medicenna Therapeutics is $114M.
-
Who are Medicenna Therapeutics’s competitors?
Xilio Therapeutics, OncoResponse, Ember Therapeutics, Xenetic Bioscience, and BioNTech are some of the 54 competitors of Medicenna Therapeutics.
-
What is Medicenna Therapeutics’s annual earnings per share (EPS)?
Medicenna Therapeutics’s EPS for 12 months was -$0.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
